Adaptive Biotechnologies ADPT Q2 2026: Revenue Beat Masks a One-Time EPS Hit
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Adaptive Biotechnologies crushed revenue expectations with a 9.3% beat, powered by 43% growth in clonoSEQ test volume, while the EPS miss came entirely from a $23.7 million one-time charge tied to extinguishing a revenue interest liability. The genomics company also raised full-year MRD revenue guidance to $268-$278 million and announced plans to separate its MRD and Immune Medicine businesses into distinct entities.
Continue ReadingShow less
Adaptive Biotechnologies posted Q2 2026 revenue of $71.6 million, beating analyst estimates of $65.5 million by more than 9%. The headline driver was clonoSEQ, the company's minimal residual disease test, which saw volume grow 43% and pushed MRD results well ahead of expectations. Revenue has climbed steadily from $43.2 million in Q2 2024, with only modest softness in the most recent two quarters after a spike to $94 million in Q3 2025.
The EPS shortfall — a reported loss of $0.25 versus an estimated loss of $0.13, a miss of roughly 87% — was not a reflection of the underlying business. The entire gap traces to a $23.7 million one-time charge for extinguishing a revenue interest liability, a balance-sheet cleanup that does not recur. Investors watching the core business trajectory have a cleaner picture once that item is stripped out.
Looking ahead, management raised full-year MRD revenue guidance to a range of $268 to $278 million, signaling confidence in continued clonoSEQ momentum. The company also announced plans to separate its MRD and Immune Medicine operations into two distinct entities, a structural move that could sharpen focus and valuation clarity for each business going forward.
Mentioned: ADPT
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.